Multicell is developing MCT-275, a immunoglobulin-peptide (Ig-Peptide), that specifically targets autoaggressive T-Cells which attack pancreatic islet cells resulting in the loss of insulin production.  MCT-275 was developed using the same Ig-Peptide therapeutic technology used to develop MCT-175. MCT-275 has demonstrated efficacy in animals of type-1 diabetes. Both humans and animals naturally have a blood glucose level of 100 milligrams (mg) per deciliter (dl). The symptoms of diabetes, such as frequent urination and lethargy, historically start when an individual’s glucose level rises to 150-200mg/dl. In animal models, MultiCell treated animals  following clinical onset of the disease (blood glucose levels were 150-200 mg/dl).  After slightly increasing (as is normal in untreated diabetes), the animals injected with MCT-275 showed a reversal in blood glucose levels. The animals which were not treated continued to have a rise in glucose until the disease progressed and resulted in death. MultiCell’s MCT-275 is expected to be tested for use in treating Type-1 diabetes, and could enter Phase I clinical trials in late 2007.